Literature DB >> 8429100

Fluctuation of HTLV-I proviral DNA in peripheral blood mononuclear cells of HTLV-I-associated myelopathy.

R Kubota1, T Fujiyoshi, S Izumo, S Yashiki, I Maruyama, M Osame, S Sonoda.   

Abstract

To assess the immunopathological significance of the increased replication of human T-cell leukemia virus type I (HTLV-I) in HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) we investigated the dynamics of HTLV-I proviral DNA in peripheral blood mononuclear cells (PBMC) of HAM/TSP patients at different clinical stages. We compared the dynamics to those of asymptomatic HTLV-I carriers (AC). The estimation of the amount of HTLV-I proviral DNA was carried out by quantitative polymerase chain reaction of serially diluted DNA samples where it was feasible to titrate 0.04-80 copies per 100 PBMC. The proviral DNA quantified in six patients with HAM/TSP was 2-20 copies per 100 PBMC, while that in eight cases of AC was 0.04-8 copies per 100 PBMC. Thus, the amount of HTLV-I proviral DNA in HAM/TSP patients was 3-50 times as high as that of AC. When we followed up HAM/TSP patients for 1-3 years, the amount of HTLV-I proviral DNA fluctuated from 4 to 10-fold. These data suggest that the rate of HTLV-I replication increases in HAM/TSP and the amount of HTLV-I proviral DNA fluctuates in their clinical course. Fluctuation in the amount of HTLV-I proviral DNA may reflect dynamics of HTLV-I infected cell proliferation and immunological suppression in vivo in HAM/TSP patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8429100     DOI: 10.1016/0165-5728(93)90004-i

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  22 in total

1.  HTLV-I proviral load correlates with progression of motor disability in HAM/TSP: analysis of 239 HAM/TSP patients including 64 patients followed up for 10 years.

Authors:  T Matsuzaki; M Nakagawa; M Nagai; K Usuku; I Higuchi; K Arimura; H Kubota; S Izumo; S Akiba; M Osame
Journal:  J Neurovirol       Date:  2001-06       Impact factor: 2.643

Review 2.  Neuroimmunity of HTLV-I Infection.

Authors:  Eiji Matsuura; Yoshihisa Yamano; Steven Jacobson
Journal:  J Neuroimmune Pharmacol       Date:  2010-05-02       Impact factor: 4.147

Review 3.  Genetic control and dynamics of the cellular immune response to the human T-cell leukaemia virus, HTLV-I.

Authors:  C R Bangham; S E Hall; K J Jeffery; A M Vine; A Witkover; M A Nowak; D Wodarz; K Usuku; M Osame
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-04-29       Impact factor: 6.237

Review 4.  Pathogenesis and treatment of HTLV-I associated myelopathy.

Authors:  G P Taylor
Journal:  Sex Transm Infect       Date:  1998-10       Impact factor: 3.519

5.  The host genomic environment of the provirus determines the abundance of HTLV-1-infected T-cell clones.

Authors:  Nicolas A Gillet; Nirav Malani; Anat Melamed; Niall Gormley; Richard Carter; David Bentley; Charles Berry; Frederic D Bushman; Graham P Taylor; Charles R M Bangham
Journal:  Blood       Date:  2011-01-12       Impact factor: 22.113

6.  cis-Acting inhibitory elements within the pol-env region of human T-cell leukemia virus type 1 possibly involved in viral persistence.

Authors:  A Saiga; S Orita; N Minoura-Tada; M Maeda; Y Aono; M Asakawa; K Nakahara; R Kubota; M Osame; H Igarashi
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

7.  Characterization and sequencing of prototypic human T-lymphotropic virus type 1 (HTLV-1) from an HTLV-1/2 seroindeterminate patient.

Authors:  A Waziri; S S Soldan; M D Graf; J Nagle; S Jacobson
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

Review 8.  Human T-lymphotropic virus type 1 (HTLV-1): persistence and immune control.

Authors:  Charles R M Bangham
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

9.  Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy.

Authors:  E Wattel; J P Vartanian; C Pannetier; S Wain-Hobson
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

10.  Evaluation of commercial HTLV-1 test kits by a standard HTLV-1 serum panel.

Authors:  C Fujiyama; T Fujiyoshi; D Matsumoto; H Tamashiro; S Sonoda
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.